MAPT and Alzheimer disease: In animal models of AD, administration of caffeine, has been associated to a reduced risk for memory decline and dysfunction, beta-amyloid production and tau hyperphosphorylation (Costa et al., 2008; Arendash et al., 2009; Canas et al., 2009; Cao et al., 2009; Eskelinen and Kivipelto, 2010; Santos et al., 2010; Laurent et al., 2014; Kaster et al., 2015; Kolahdouzan and Hamadeh, 2017).